Table 1.
Patient | Sample ID | Unit | Specimen date | Sample type | Age (years) | Sex | Diagnosis | Antibiotic therapy | Status at discharge |
---|---|---|---|---|---|---|---|---|---|
1 | NM01 | SMRU | 25/7/07 | CSF | 7 | M | Meningitis | Unknown | Unknown |
2 | NM03 | SMRU | 25/11/09 | BC | 1 | F | Sepsis | Ceftriaxone | Well |
3 | NM04 | SMRU | 15/11/10 | BC | <1 | M | Meningitis | Ceftriaxone | Well |
4 | NM06 | SMRU | 19/6/11 | BC | 0.2 | M | Meningitis | Unknown | Unknown |
5 | NM07 | SMRU | 4/10/11 | BC | 0.5 | M | Meningitis | Ceftriaxone | Well |
6 | NM09 | SMRU | 7/1/12 | BC | 0.2 | M | Meningitis | Ceftriaxone | Well |
7 | NM11 | SMRU | 18/1/12 | BC | 3 | M | Meningitis | Ceftriaxone | Well |
8 | NM12 | SMRU | 28/12/12 | BC | 0.3 | F | Sepsis | Ceftriaxone | Well |
9 | NM13 | SMRU | 13/5/13 | BC | 0.6 | M | Sepsis | Ceftriaxone | Well |
10 | NM14 | SMRU | 15/2/14 | BC | 0.3 | F | Sepsis | Ceftriaxone | Well |
11 | NM15 | SMRU | 19/12/14 | BC | 0.3 | M | Sepsis | Unknown | Well |
12 | NM16 | LOMWRU | 10/11/17 | CSF | 60 | F | Meningitis | Ceftriaxone | Well |
13 | NM18 | COMRU | 13/10/13 | BC | 0.14 | F | Meningitis/Sepsis | Ceftriaxone | Well |
14 | NM19 | COMRU | 25/4/14 | BC | 1.84 | F | Sepsis | Ceftriaxone | Well |
15 | NM20 | COMRU | 31/3/15 | BC | 0.91 | F | Pneumonia/Sepsis | Ceftriaxone | Well |
16 | NM21 | COMRU | 24/7/16 | BC | 0.07 | M | Meningitis/Sepsis | Unknown | Well |
17 | NM23 | COMRU | 22/8/17 | BC | 0.33 | F | Meningitis | Ceftriaxone | Well |
18 | NM25 | LOMWRU | 21/3/18 | BC | 0.25 | M | Meningitis | Ceftriaxone | Well |
SMRU, Shoklo Malaria Research Unit, Mae Sot, Thailand; LOMWRU, Lao-Oxford-Mahosot Hospital Wellcome Trust Research Unit, Vientiane, Laos; COMRU, Cambodia Oxford Medical Research Unit, Siem Reap, Cambodia.
CSF, cerebrospinal fluid; BC, blood culture.